Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050) - Lung Cancer
PP-DAC-USA-0041 VIZIMPRO® (dacomitinib) Fact Sheet ABOUT VIZIMPRO VIZIMPRO® (dacomitinib) is a kinase inhibitor for the first-
Please note these are the actual videorecorded proceedings
EGFR-targeted treatments: insights from the adjuvant to the resistant setting - memoinOncology
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050) - Lung Cancer
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-sm | OTT
Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer - Carpenter - Journal of Thoracic Disease
P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050 - Journal of Thoracic Oncology
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR -Activating Mutations | SpringerLink
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - ScienceDirect
VIZIMPRO® (dacomitinib) Efficacy | Safety Info
Table 2 from Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. | Semantic Scholar
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.,Cancer Science - X-MOL
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. | Semantic Scholar
Dacomitinib in lung cancer: a "lost generation" EGFR tyros | DDDT
Summary of median overall survival (OS) and progression-free survival... | Download Table
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials - ScienceDirect
Vizimpro 45 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Kaplan-Meier curves show (A) progression-free survival and (B) overall... | Download Scientific Diagram
CONVERT trial<br />Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurre
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials - Annals of Oncology
